Related Experiment Videos

Melatonin ameliorates Aβ1-42 -induced Alzheimer's cognitive deficits in mouse model

Yu-Hang Gong1, Nan Hua1, Xuan Zang1

  • 1Department of Pharmacology, China Pharmaceutical University, Nanjing, China.

Abstract

Insights

Melatonin improved cognitive function in Alzheimer's disease (AD) mice by reducing amyloid-beta (Aβ) and tau pathology, and alleviating mitochondrial damage.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) plaques and tau pathology.
  • Cognitive decline and mitochondrial dysfunction are key features of AD.

Purpose of the Study:

  • To investigate melatonin's efficacy in ameliorating cognitive deficits in an Aβ₁-42-induced AD mouse model.
  • To elucidate the underlying mechanisms, including effects on Aβ, tau, apoptosis, and mitochondrial function.

Main Methods:

  • Behavioral tests assessed cognitive function in AD mice.
  • ELISA and Western blot analyzed protein expression (Aβ₁-42, BACE1, p-tau, caspase-3, Bcl-2, GSK-3β, PP2A).
  • JC-1 assay evaluated mitochondrial damage in vitro.

Main Results:

  • Melatonin significantly improved cognitive function and reduced mitochondrial damage in AD mice.
  • Melatonin decreased levels of Aβ₁-42, BACE1, p-tau, GSK-3β, and caspase-3.
  • Melatonin increased levels of PP2A and Bcl-2.

Conclusions:

  • Melatonin effectively alleviates mitochondrial damage and reduces key proteins associated with AD pathology and apoptosis.
  • These actions contribute to the observed improvement in cognitive function in the Aβ₁-42-induced AD mouse model.

Related Concept Videos